ARTICLE | Company News
ImmunoGen, Boehringer Ingelheim International GmbH deal
December 3, 2001 8:00 AM UTC
The companies will develop a therapeutic that combines IMGN’s Tumor Activated Prodrug (TAP) technology with a Boehringer antibody targeting CD44. TAP technology combines a tumor targeting antibody wi...